Clinical trial

MARGetuximab Or Trastuzumab (MARGOT)

NCT04425018

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-07-13

PhasePHASE2

Study timeline

Study start (actual)2020-07-13Date precision: day

Registry last updated2025-11-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Stage II Breast Cancerunresolved

Stage III Breast Cancerunresolved

HER2-positive Breast Cancerunresolved

Interventions

PaclitaxelDRUG · verified · RxNorm: paclitaxel

PertuzumabDRUG · verified · RxNorm: pertuzumab

MargetuximabDRUG · verified · RxNorm: margetuximab

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

Dana-Farber Cancer Institutelead sponsor

MacroGenicscollaborator

Translational Breast Cancer Research Consortiumcollaborator

Mapped research locations

HoustonTexas, United States2 BostonMassachusetts, United States2 Washington D.C.District of Columbia, United States2 SeattleWashington, United States1 PittsburghPennsylvania, United States1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04425018 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.